H.C. Wainwright analyst Matt Caufield reiterated a Buy rating and $12.00 price target on DiaMedica Therapeutics Inc. (NASDAQ: DMAC).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE